Open-Source vs. Proprietary AI in Healthcare: Questions to Ask After the Musk v. OpenAI Revelations

Hospitals must ask hard questions now: What the Musk v. OpenAI unsealed documents teach procurement teams about open-source vs. proprietary AI

Hook: If your hospital is buying AI-powered clinical tools in 2026, you likely share three frustrations: unclear model provenance, hidden open-source components, and uncertain vendor liability when things go wrong. The unsealed documents from the Musk v. OpenAI case — and a wave of regulatory activity in late 2025 — make one thing plain: procurement teams must treat AI suppliers like high-risk medical device vendors. This article gives a practical, evidence-backed due-diligence playbook you can use today.

Why this matters now (short answer)

In late 2025 and early 2026, enforcement and public scrutiny of AI supply chains accelerated. Regulators (including EU AI Act enforcement pilots and updated U.S. guidance aligned with NIST frameworks) pressured vendors to document training data provenance, governance, and risk mitigation. Meanwhile, the Musk v. OpenAI unsealed filings highlighted internal disagreements about how open-source models and components are treated inside commercial offerings — a reminder that open-source code or weights can be embedded, modified, and repackaged inside proprietary stacks.

"Unsealed documents from Musk v. OpenAI reveal concerns inside the industry about treating open-source AI as a 'side show' — and the real operational and legal consequences that follow."

For hospitals, that means procurement teams must verify what’s running under the hood before signing contracts that touch PHI, care decisions, or clinical workflows.

High-level tradeoffs: open-source vs proprietary models (2026 lens)

Understanding the core tradeoffs will help you choose meaningful due-diligence questions.

• Open-source models: Greater transparency and inspectability; faster security fixes from the community; potential licensing and copyleft obligations; variable support and inconsistent governance; higher risk if models are forks of unverified weights.
• Proprietary models: Vendor-managed support, warranty promises, and SLAs; less transparency into weights and training data; potential vendor lock-in; often stronger contractual liability tooth (but check the fine print).

Both model classes present privacy and regulatory risk when used with protected health information (PHI). The key is auditable provenance, verifiable governance, and contractual accountability.

What procurement should demand: the evidence and documents to request

Begin each procurement with a standardized documentation packet. Require these artifacts up front and in the contract:

1. Model Bill of Materials (MBOM) — a machine- and human-readable inventory listing base model(s), version hashes, third-party libraries, and licenses.
2. Training-data provenance report — high-level description of data sources used for pretraining and fine-tuning, plus provenance metadata and evidence of consent/data licensing for any third-party PHI-derived sources.
3. Model cards and data sheets — performance metrics, intended use cases, evaluation datasets, limitations, and recommended guardrails.
4. Audit logs and evaluation reports — model evaluation artifacts, test suites used for clinical validation, and red-team/adversarial test results.
5. Governance and change-control policy — how updates/patches, model drift, or retraining are approved, communicated, and rolled back.
6. Security attestations — SOC 2/ISO 27001, SBOM for code, and third-party penetration test reports for hosted inference endpoints.
7. Compliance documentation — HIPAA Business Associate Agreement (BAA), DPA, and any country-specific compliance attestations.
8. Liability and indemnity terms — cyber insurance specifics, indemnity for regulatory fines, and limits on consequential damages.

Actionable due-diligence question set (use as a procurement checklist)

Below are precise questions, grouped by theme. Use them during RFPs, vendor meetings, and contract negotiations. Ask for written evidence and testable artifacts — not just assurances.

Model provenance and lineage

• What is the exact base model (name and version) used? Provide commit hashes, model weight checksums, and release tags.
• Which open-source projects or third-party models were incorporated or forked? Provide license compliance evidence and a signed MBOM.
• Can you provide a reproducible build manifest that shows how the final inference artifact was assembled from base components?
• Are there internal forks or modifications to public weights? If so, provide a diff summary and justification for each change.

Data handling and HIPAA considerations

• Does the model use or retain any PHI during training, fine-tuning, or inference? If yes, provide documented lawful basis and data minimization steps.
• How is PHI protected in transit and at rest? Provide encryption standards, key management, and access control logs.
• Is the vendor willing to sign a HIPAA BAA that covers all subcontractors and cloud providers in the inference path?
• What de-identification techniques were used on training data? Provide re-identification risk assessment results.

Open-source components and licensing risk

• List all open-source licenses present in the MBOM. Are any copyleft or viral licenses present that could impose redistribution obligations?
• How does the vendor monitor upstream open-source vulnerabilities and license changes? Provide SLAs for security patching.
• Have any legal opinions been obtained on license compliance (e.g., GPL, AGPL implications)? Provide redacted legal memoranda if available.

Governance, updates, and change control

• What is the formal governance body for the model (roles, approval thresholds, and meeting cadence)?
• How are model updates communicated to customers? Provide notification timelines and rollback procedures.
• Is there an automated CI/CD pipeline for model updates? Provide an architecture diagram showing test gates and approvals.

Auditability and clinical validation

• Provide clinical validation reports, including sample sizes, metrics, and dataset provenance for each evaluation.
• Do you support third-party audits of the model and infrastructure? If so, what are the terms and frequency, and who pays?
• Can the vendor provide a sealed test corpus (non-PII) that a hospital can use to run independent accuracy and bias checks?

Security, incident response, and resilience

• Provide the most recent third-party penetration test and results for inference endpoints and model management systems.
• What are the vendor’s breach notification timelines? Commit to HIPAA-mandated windows (and faster, if feasible).
• How does the vendor defend against model-extraction and prompt-injection attacks? Provide documented mitigations and test results.

Liability, indemnity, and insurance

• What is the vendor’s cyber and professional liability insurance coverage (limits and endorsements)?
• Will the vendor indemnify the hospital for third-party claims arising from IP infringement or regulatory penalties tied to model behavior?
• Are there carve-outs or caps in the contract that limit vendor responsibility for model misdiagnosis or erroneous outputs? Negotiate explicit language if present.

Red flags to watch for (procurement redlines)

Some vendor responses are warnings — treat them as non-starters unless mitigated:

• Refusal to provide MBOM, model hash, or reproducible build manifests.
• Blanket statements that the model is proprietary and "trade secret" without any auditor access or independently verifiable evidence.
• BAA refusal or vague subcontractor coverage disclaimers.
• Excessive liability caps that leave you to bear regulatory fines or patient harms.
• Opaque use of open-source components without license-compliance evidence.

Contract clauses and enforcement mechanisms procurement should insist on

Translate your due-diligence findings into enforceable contract language. Key clauses:

• Audit rights: Right to annual third-party audits and immediate ad-hoc audits after any incident.
• Model provenance warranty: Vendor warrants that the MBOM is complete and that all components were lawfully obtained and licensed.
• Change control and notification: 30–60 day prior notice for non-critical model changes; emergency patching procedures defined.
• Indemnity for regulatory fines: Vendor indemnifies the hospital for penalties resulting from vendor negligence tied to data handling or misrepresentations.
• Service-level agreements (SLAs): Uptime, response time, and defined rollback/recall procedures for faulty models.
• Data handling annex: Explicit BAA covering sub-processors, encryption, key management, and PHI usage limits.

How to verify vendor claims: technical and organizational tests

Ask for demonstrable evidence, not promises. Use this shortlist of verification steps:

• Checksum verification: Verify model weight hashes against the vendor’s supplied MBOM. If a vendor claims a known open-source base, the hashes should match public releases.
• Reproducible build test: With vendor-supplied artifacts, ask an internal or third-party engineer to reproduce an inference artifact in a sandbox.
• Red-team and adversarial testing: Run prompt-injection, data-exfiltration, and model-extraction scenarios against a staging instance.
• Clinical acceptance testing (CAT): Use a sealed, realistic test set to validate clinical performance in your environment before go-live.
• Periodic drift checks: Implement scheduled performance and fairness monitoring with defined remediation triggers.

Case study (compact): How a mid-size hospital avoided a licensing trap in 2025

In late 2025, a regional health system negotiated with an AI vendor that offered a clinical summarization tool. The vendor refused to supply an MBOM, claiming commercial sensitivity. Procurement and legal insisted on an auditor-led verification. The third-party audit revealed that the vendor had used an AGPL-licensed component in the inference stack without compliance steps — a potential requirement to disclose source code and distribution. The hospital walked away and selected a vendor that provided full MBOMs and a signed license-compliance attestation. The learning: insist on MBOMs early. It preserves negotiating leverage and prevents post-deployment exposure to copyleft obligations and unexpected IP risk.

Regulatory context and 2026 trends you must plan for

Regulation is catching up. Key developments as of January 2026:

• EU AI Act enforcement pilots (late 2025) focused on high-risk AI in healthcare, requiring transparency, documentation, and risk assessments.
• NIST and U.S. guidance updates (2025–2026) clarified expectations for model provenance, SBOM-equivalent artifacts, and AI risk management practices.
• OCR and HIPAA scrutiny increased around AI vendors' BAAs and breach reporting; hospitals are now being asked for proof of vendor audits during OCR reviews.
• Market shift to verifiable provenance — purchasers increasingly expect MBOMs, model cards, and reproducible evaluation artifacts as table stakes.

These trends mean that hospitals that demand stronger provenance and contractual protections gain both regulatory resilience and bargaining power.

Template: Minimum acceptable evidence list (quick reference)

Ask vendors to supply — delivered digitally and cryptographically signed — the following before pilot approval:

• Signed MBOM with component hashes
• Model card and evaluation reports
• Training-data provenance statement and re-identification risk assessment
• Signed HIPAA BAA covering sub-processors and cloud providers
• Third-party SOC 2/ISO 27001 attestation and latest penetration test report
• Proof of cyber insurance and indemnity language draft
• Demonstration of rollback and emergency patch procedures

Balancing transparency with trade secrets

Vendors will legitimately raise trade-secret concerns. You can balance this by:

• Agreeing to redacted MBOMs or auditor-only full MBOM access under NDA.
• Contracting for independent third-party audits with signed nondisclosure that report only compliance outcomes.
• Using technical attestations (checksum verification, cryptographic signatures) in lieu of full public disclosure when necessary.

Final practical steps for procurement teams (30–60 day plan)

1. Update your RFP template to include MBOM, model-card, and BAA requirements.
2. Train procurement, legal, and clinical engineering on the due-diligence question set above.
3. Run a pilot acceptance test that includes checksum verification, CAT, and adversarial tests.
4. Negotiate contract clauses for audits, indemnity, and emergency rollback before production sign-off.
5. Implement continuous monitoring and quarterly drift/fairness reports as contract deliverables.

Key takeaways

• Demand provenance: Model Bill of Materials and weight hashes are not optional.
• Treat open-source as material: Open-source components can create license, security, and governance risk if untracked.
• Contract for accountability: Audit rights, indemnity, and BAAs are core protections for hospitals handling PHI.
• Verify technically: Independent audits, reproducible builds, and CATs are essential before deployment.

Closing: a pragmatic call-to-action

Start your procurement checklist overhaul now. Use the question set and documentation demands in this article as your baseline; adapt them for local legal and clinical requirements. If you need a ready-to-use RFP template, MBOM schema, or third-party auditor recommendations tailored for healthcare, contact a trusted security and legal advisor who specializes in AI for clinical use. The time to require verifiable model provenance—and to insist on enforceable vendor responsibility—is now.

Next step: Download our AI procurement checklist (MBOM template and sample contract clauses) or schedule a 30-minute advisory review to evaluate a pending AI vendor. Protect patients, protect your institution, and demand auditable AI.

Related Reading

• How to Host Live Twitch/Bluesky Garden Workshops That Actually Grow Your Audience
• How to Ride Platform Migration Waves: Lessons from Bluesky’s Surge After X Drama
• Build a 'Dining Decision' Micro App: From Prompt to Production in Seven Days
• How Athlete-Led Production Deals Can Amplify Women’s Sport Narratives
• How to Reroll Your Build in Nightreign After the Executor Buff